Drugs / CP-601,927
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01396135 | Aug → Oct 2011 | — | Pfizer | Withdrawn | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01098240 | Jun 2010 → Sep 2011 | major depressive disorder | Pfizer | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-601,927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01098240 ↗ |
| Modality | Small molecule | — CHEMBL3341965 ↗ |
| Route | Oral | “CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.” NCT01098240 ↗ |